

# Cefepime

Cefepime is a fourth-generation [cephalosporin antibiotic](#). Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organisms than third-generation agents.

A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other  $\beta$ -lactam antibiotics.

In response, the U.S. Food and Drug Administration performed its own meta-analysis which found no mortality difference.

Cefepime was developed by Bristol-Myers Squibb and marketed beginning in 1994. It is now available as a generic drug and sold under a variety of trade names worldwide.

---

For a [superficial wound infection](#) start the patient empirically on [vancomycin](#) plus [cefepime](#) or [meropenem](#)

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=cefepime>

Last update: **2024/06/07 02:57**

